The "Dream Changer": a randomized controlled trial evaluating the efficacy of a parent-based intervention for childhood nightmares.


Journal

Sleep
ISSN: 1550-9109
Titre abrégé: Sleep
Pays: United States
ID NLM: 7809084

Informations de publication

Date de publication:
11 04 2022
Historique:
received: 26 08 2021
revised: 16 11 2021
pubmed: 19 2 2022
medline: 13 4 2022
entrez: 18 2 2022
Statut: ppublish

Résumé

Recurrent nightmares in childhood may have a range of detrimental effects for both the child and parents. This randomized controlled trial evaluated the efficacy of a novel parent-based intervention for childhood nightmares, using a new device called the "Dream Changer." A total of 56 children aged 3-10 years (M = 7.1 ± 2.1 years; 51.8% boys), and one of their parents were randomized to either the intervention or waitlist control group. The intervention group received a "Dream Changer"-a light-emitting remote-control-like device that the child was encouraged to take to bed and use upon experiencing a nightmare. Parents completed online surveys at baseline, 1-week, and 2-weeks following the intervention. Parents in the intervention group additionally completed a 3-month follow-up survey. Outcome variables included children's nightmare frequency, sleep-wake patterns, and sleep anxiety, as well as parents' daytime sleepiness. Significant group-by-time interaction effects were found for nightmare frequency (p = 0.001) and sleep anxiety (p = 0.006). Parents of children who received the "Dream Changer" reported fewer nightmares (Mdifference = 1.7, p < 0.001, d = 1.06) and decreased anxiety (Mdifference = 0.9, p = 0.001, d =0.41) at post-intervention, whereas such benefits were not found in the waitlist control group. Three-month follow-up assessments demonstrated that gains were maintained over-time. Interaction effects were not significant for children's sleep metrics or for parents' daytime sleepiness. The present study provides preliminary evidence for the efficacy of a brief, highly accessible intervention for reducing children's nightmares and nighttime anxiety. Future research may wish to test these effects using larger samples and longer follow-up assessments. The trial has been registered at the Australian New Zealand Clinical Trials Registry (https://www.anzctr.org.au/; Identifier:ACTRN12620000633987).

Identifiants

pubmed: 35179573
pii: 6531959
doi: 10.1093/sleep/zsac004
pii:
doi:

Banques de données

ANZCTR
['ACTRN12620000633987']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of Sleep Research Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Stephanie Bourboulis (S)

College of Education, Psychology & Social Work, Flinders University, Adelaide, Australia.
College of Education, Psychology & Social Work, Flinders University, Adelaide, Australia.

Michael Gradisar (M)

College of Education, Psychology & Social Work, Flinders University, Adelaide, Australia.
WINK Sleep Pty Ltd, Adelaide, Australia.

Michal Kahn (M)

College of Education, Psychology & Social Work, Flinders University, Adelaide, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH